Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07289763
Recruiting Phase 2

Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

NCT07289763 · tracked via the Priya Life Science China tracker
Sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase
Phase 2
Started
2025-12-31
Last updated
2026-01-26

Condition(s) studied

Primary Membranous Nephropathy

Investigational drug(s) / intervention(s)

SHR-2173 injection →SHR-2173 injection →SHR-2173 injection →

SHR-2173 injection: SHR-2173 injection, with a total of 8 administrations

SHR-2173 injection: SHR-2173 injection, with a total of 16 administrations

SHR-2173 injection: SHR-2173 injection , with a total of 32 administrations

Study summary

To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age 18-75 years, regardless of gender; 2. Weight ≥40.0 kg at screening; 3. Diagnosed as primary membranous nephropathy through kidney biopsy. Exclusion Criteria: 1. Secondary membranous nephropathy. 2. Subjects developed rapidly progressive glomerulonephritis or required kidney transplantation. 3. Subjects who have undergone kidney dialysis in the previous 12 months or are expected to require dialysis during the study period. 4. Subjects who have a malignant tumor or a history of malignant tumor 5. Subjects who have undergone major surgery within the previous 3 months, or plan to undergo major surgery during the study period.

Primary outcome measure(s)

  • Adverse events — Week0, 2, 4, 8, 12,16, 20, 24, 28, 32, 36, 40, 48 52
  • 12-lead ECG — Week4, 8, 12, 24, 28, 36, 52

Trial sites (1)

FacilityCityRegionStatus
General hospital of eastern theater command Nanjing Jiangsu Recruiting

More Guangdong Hengrui Pharmaceutical Co., Ltd trials in China

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia Recruiting
A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis Recruiting
A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults Recruiting
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With Moderate-to-severe Active Ulcerative Colitis Active, not recruiting
A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors Active, not recruiting

Other trials for the same condition

Study of YK012 in Primary Membranous Nephropathy Recruiting
Optimization of a Decision Formula for Optimal Timing of Immunosuppressive Therapy Initiation in Primary Membranous Nephropathy: A Multicenter Retrospective Cohort Study Active, not recruiting
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy. Recruiting
The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy Starting soon
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07289763 on ClinicalTrials.gov ↗ ← All trials in China